[Basic and clinical studies on cefminox in the field of obstetrics and gynecology].
Fundamental and clinical studies on cefminox (CMNX, MT-141), a new cephamycin antibiotic, were performed and the following results were obtained. Concentration of CMNX was examined in serum, internal genital organs and retroperitoneal fluid after a single intravenous administration of 1.0 g dose. The venous serum level of CMNX was 62.8 +/- 7.02 microgram/ml (Mean +/- S.D.) at 30 minutes after the administration. The sufficient transfer of CMNX to internal genital organs and retroperitoneal fluid was demonstrated. In clinical trial, CMNX was given to 10 cases with obstetrical and gynecological infections. The efficacy was evaluated as excellent in 1 case, good in 8 cases and poor in 1 case. No side effects were observed in any of the cases treated with CMNX.
D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D002513:Cephamycins / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use*; D004716:Endometritis / Q000188:drug therapy; D005122:Exudates and Transudates / Q000378:metabolism; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D006801:Humans; D007700:Kinetics; D008875:Middle Aged; D010053:Ovary / Q000378:metabolism; D014599:Uterus / Q000378:metabolism
D002513:Cephamycins; C046079:cefminox